Quick Answer
MiNK Therapeutics, Inc. reported Operating Income of -$12.64 million for fiscal year 2025.
MiNK Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$12.64M | -12.0% |
| 2024 | -$11.29M | +50.8% |
| 2023 | -$22.92M | +25.9% |
| 2022 | -$30.95M | -9.1% |
| 2021 | -$28.36M | -93.7% |
| 2020 | -$14.64M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.18M | -68.9% | +21.4% |
| June 30, 2025 | -$4.05M | -32.0% | -50.1% |
| March 31, 2025 | -$2.70M | +29.5% | -43.3% |
| September 30, 2024 | -$1.88M | +63.9% | +38.6% |
| June 30, 2024 | -$3.07M | +51.6% | +19.8% |
| March 31, 2024 | -$3.83M | +34.6% | +26.7% |
| September 30, 2023 | -$5.22M | +34.6% | +17.7% |
| June 30, 2023 | -$6.34M | +17.6% | -8.4% |
- MiNK Therapeutics, Inc. showed a decrease of -12.0% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, MiNK Therapeutics, Inc.’s operating income has grown by 13.6% (from -$14.64 million to -$12.64 million).
- The most recent figure is from MiNK Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: